ClinicalTrials.gg
CompletedNCT05052437Updated Jan 10, 2023

PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer

A Phase 1 interventional study of Utidelone Injection; capecitabine and Utidelone in Advanced and Metastatic Breast Cancer, sponsored by Beijing Biostar Pharmaceuticals Co., Ltd.. Completed at 2 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-01-10.

Sponsored by Beijing Biostar Pharmaceuticals Co., Ltd. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Oct 2020, registered May 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing desoxyepothilone B in Breast Neoplasms — 8 open to participants now, 9 under way, 4 of them phase 3. desoxyepothilone B · Breast Neoplasms.

Enrollment
14th of 14
16 · median 110
Started
2020
the only one that year
Phase 1
Only one
of the 14
Registered
3rd of 14
by date
Lead sponsor
4 of 14
Beijing Biostar Pharmaceuticals Co., Ltd.

Among the 14 studies testing desoxyepothilone B in Breast Neoplasms, this one is the 14th largest by enrollment, is the only one that started in 2020, is the only one in phase 1, and was the 3rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 14 studies testing desoxyepothilone B in Breast Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About desoxyepothilone B

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing desoxyepothilone B in Breast Neoplasms, or all of them as a file.
02

Study summary

This trial is an open, multi-center, phase Ic clinical study on the pharmacokinetics and drug interactions of utidelone injection combined with capecitabine in patients with recurrent and metastatic breast cancer.

The purpose of this trial is:

  1. To evaluate the pharmacokinetic characteristics of continuous intravenous administration of utidelone.
  2. To evaluate the drug interaction of utidelone and capecitabine.
03

Conditions studied

  • Advanced and Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign an form, have good compliance, and cooperate with relevant inspections.
  2. and/or cytologically diagnosed patients with advanced, breast cancer.
  3. Patients who have previously received at least one anthracycline and taxane drug therapy ( therapy, adjuvant therapy, or recurrence and metastasis therapy), or the investigator believes that they can be included in this study.
  4. Age ≥18 years; physical condition score 0\~2 points.
  5. Within 4 weeks before enrollment, Neuropathy should be less than grade 2 ( 5.0).
  6. Within 1 week before enrollment, routine blood examinations were basically normal (based on the normal value of each research center laboratory):

    1. White blood cell count (WBC) ≥3.0×109/L;
    2. (ANC) ≥ 1.5×109/L;
    3. count (PLT) ≥100×109/L.
    4. ≥9g/dL.
  7. Within 1 week before enrollment, liver and kidney function tests were basically normal (the normal value of each research center laboratory is standard):

    1. Total (TBIL)≤1.5× (ULN);
    2. (SGPT/ALT)≤2.5×ULN (for liver metastases≤5×ULN);
    3. Aspartate aminotransferase (SGOT/AST)≤2.5×ULN (for liver metastases≤5×ULN);
    4. rate (Ccr) ≥60 ml/min.
  8. No major organ dysfunction.
  9. The patient must agree to provide blood, urine and stool samples for pharmacokinetic studies, and collect them in strict accordance with the required time points and intervals.
  10. No mental abnormality, able to understand and undertake informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Those who need to receive non-investigative anti-cancer therapy (such as chemotherapy, immunotherapy or biological therapy) during the administration period of this trial.
  2. People who are severely allergic to castor oil, or who have had serious adverse reactions to anti-microtubule drugs in the past.
  3. Within 4 weeks before receiving treatment, have had any major surgery or suffered major trauma; or are expected to undergo major surgery during the treatment.
  4. Pregnancy (positive pregnancy test), breastfeeding patients, or those who are unwilling to use during the test;
  5. Those with uncontrollable intracranial hypertension syndrome (persistent headache, short-term blurred vision, and/or diplopia)
  6. Combined serious diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled high blood pressure, severe infection, active peptic ulcer, etc.
  7. Known infection, or untreated active or C;
  8. Known to have alcohol or drug addiction, or have a history of uncontrollable mental illness, lack of legal capacity or limited legal capacity;
  9. The investigator believes that it is inappropriate to participate in this trial.
  10. Participate in another clinical trial or use other research treatments at the same time.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Utidelone

    Drug: Utidelone

  • Experimental
    Utidelone plus capecitabine

    Drug: Utidelone Injection; capecitabine

Interventions

  • DrugUtidelone Injection; capecitabine

    Drug pages: Desoxyepothilone B · Capecitabine

    8 patients will be assigned to utidelone plus capecitabine arm receiving utidelone plus capecitabine. Utidelone injection 30mg/m2/day, intravenously administered once a day for 5 consecutive days; capecitabine tablets, 1000mg/m2, orally, 2 times a day for 14 consecutive days. 21 days is a cycle

  • 8 patients will be assigned to utidelone arm and receive utidelone injection 30 mg/m2/day intravenously, once a day for 5 consecutive days in a 21-day cycle.

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    To measure the maximal plasma concentration of the study drugs and evaluate the pharmacokinetic characteristics of continuous intravenous administration of utidelone, measure PK parameters such as Maximum Plasma Concentration \[Cmax\]

    Time frame: 12 weeks

  2. C-T curve

    To evaluate the pharmacokinetic interaction of utidelone and capecitabine in patients when administered in combination.

    Time frame: 12 weeks

  3. Area under the plasma concentration versus time curve (AUC)

    To get area under the plasma concentration versus time curve

    Time frame: 12 weeks

Secondary outcomes

  1. Measure and plot r-t curve

    To analyse mass balance

    Time frame: 12 weeks

  2. Incidence of treatment-related adverse events as assessed by CTCAE v4.0

    To evaluate the safety of the study

    Time frame: 6 months

07

Study locations

2 sites
  • Hunan Cancer Hospital
    Changsha, Hunan, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Jan 2021, 2 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 2 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2021
First posted
Sep 22, 2021
StartActual
Oct 15, 2020
Primary completionActual
Jan 13, 2021
CompletionActual
Feb 19, 2021
Last update
Jan 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05052437
Lead sponsor
Beijing Biostar Pharmaceuticals Co., Ltd.
Collaborators
Chengdu Biostar Pharmaceuticals
Responsible party
Sponsor
First posted
Sep 22, 2021
Start date
Oct 15, 2020
Primary completion
Jan 13, 2021
Completion
Feb 19, 2021
Last update
Jan 10, 2023

Study contacts

Quchang Ouyang, MD
principal investigator · Hunan Cancer Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Desoxyepothilone B · Capecitabine

Start the discussion